Browse Studies — Arctuva

Phase 1

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how…

Gastric CancerGastric AdenocarcinomaGastric (Stomach) Cancer+11 more

Estimated

~$10 – $8,750

BigHat Biosciences, Inc.NCT07529808

Phase 1

A Phase 1b/II Study of Intratumoral CD40 Agonist 2141-V11 in Combination With Anti PD-1 and 5-Fluorouracil Therapy in Patients With Advanced Gastroesophageal Adenocarcinoma

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatm…

Esophageal CancerAdvanced Esophageal CancerGastric Cancer+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07818018

Phase 1

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), …

Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal Cancer+4 more

Estimated

~$10 – $7,500

BeiGeneNCT06585488